Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLAT-05: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
NCT03330691Phase 1Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- Nov 2017
- Primary completion
- Sep 2023
- Countries
- 2
01
Overview
Phase 1, open-label trial in leukemia (2 arms), sponsored by Seattle Children's. Primary endpoints: Adverse Events at 30 days and Number of successfully and unsuccessfully manufactured and infused CAR T-cell products at 28 days. Started Nov 2017; status: active, not recruiting.
02
Conditions
leukemia
Beyond the preview
Go deeper on NCT03330691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330691.